J
Javier Crespo
Researcher at University of Cantabria
Publications - 427
Citations - 12730
Javier Crespo is an academic researcher from University of Cantabria. The author has contributed to research in topics: Medicine & Fatty liver. The author has an hindex of 43, co-authored 347 publications receiving 9598 citations. Previous affiliations of Javier Crespo include Carlos III Health Institute & University of the Basque Country.
Papers
More filters
Journal ArticleDOI
Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2 IMPLICATIONS FOR CROHN′S DISEASE
Naohiro Inohara,Yasunori Ogura,Ana Fontalba,Olga Gutierrez,F. Pons,Javier Crespo,Koichi Fukase,Seiichi Inamura,Shoichi Kusumoto,Masahito Hashimoto,Simon J. Foster,Anthony P. Moran,Jose L. Fernandez-Luna,Gabriel Núñez +13 more
TL;DR: NOD2 mediates the host response to bacterial muropeptides derived from peptidoglycan, an activity that is important for protection against Crohn's disease and has implications for understanding adjuvant function and effective vaccine development.
Journal ArticleDOI
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes,Quentin M. Anstee,María Teresa Arias-Loste,Heike Bantel,Stefano Bellentani,Joan Caballería,Massimo Colombo,Antonio Craxì,Javier Crespo,Christopher P. Day,Yuichiro Eguchi,Andreas Geier,Loreta A. Kondili,Daniela C. Kroy,Jeffrey V. Lazarus,Rohit Loomba,Michael P. Manns,Giulio Marchesini,Atsushi Nakajima,Francesco Negro,Salvatore Petta,V. Ratziu,Manuel Romero-Gómez,Arun J. Sanyal,Jörn M. Schattenberg,Frank Tacke,Junko Tanaka,Christian Trautwein,Lai Wei,Stefan Zeuzem,Homie Razavi +30 more
TL;DR: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed, if obesity and DM continue to increase at current and historical rates.
Journal ArticleDOI
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
TL;DR: A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH.
Journal ArticleDOI
Gene expression of tumor necrosis factor [alpha ] and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients
Javier Crespo,A. Cayon,Pedro Fernandez-Gil,Manuel Hernández-Guerra,Marta Mayorga,Agustín Domínguez-Díez,José Carlos Fernández-Escalante,Fernando Pons-Romero +7 more
TL;DR: Findings suggest that the TNF‐α system may be involved in the pathogenesis of NASH and the levels of mRNA‐p55 are increased in the liver tissue of NASh patients.
Journal ArticleDOI
Adiponectin and its receptors in non-alcoholic steatohepatitis
Susanne Kaser,Alexander R. Moschen,A. Cayon,Arthur Kaser,Javier Crespo,Fernando Pons-Romero,Christoph Ebenbichler,J. R. Patsch,Herbert Tilg +8 more
TL;DR: Low liver expression of adiponectin and its receptors in morbidly obese patients undergoing bariatric surgery might be of pathophysiological relevance in non-alcoholic fatty liver diseases.